111 related articles for article (PubMed ID: 37879772)
1. Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
Amori G; Sugawara E; Inamura K
J Thorac Oncol; 2023 Nov; 18(11):e134-e135. PubMed ID: 37879772
[No Abstract] [Full Text] [Related]
2. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.
Sumii M; Namba M; Tokumo K; Yamauchi M; Okamoto W; Hattori N; Sugiyama K
Intern Med; 2023 Oct; 62(20):3001-3004. PubMed ID: 36858519
[TBL] [Abstract][Full Text] [Related]
4. Probing Mutant KRAS, STK11, KEAP1 in NSCLC.
Cancer Discov; 2022 Oct; 12(10):2226. PubMed ID: 35997519
[TBL] [Abstract][Full Text] [Related]
5. Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level.
Bazhenova L
Ann Oncol; 2023 Apr; 34(4):327-332. PubMed ID: 37061249
[No Abstract] [Full Text] [Related]
6. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
[TBL] [Abstract][Full Text] [Related]
8. Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
[TBL] [Abstract][Full Text] [Related]
9. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
[TBL] [Abstract][Full Text] [Related]
10. A STING operation to expose KRAS and STK11 co-mutated lung cancers.
Skoulidis F; Heymach JV; Cascone T
Cancer Cell; 2022 Oct; 40(10):1073-1076. PubMed ID: 36220070
[TBL] [Abstract][Full Text] [Related]
11. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
[TBL] [Abstract][Full Text] [Related]
12. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
13. The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.
Long Y; Tang Y; Cai C; Yu M; Zhang M; Chen R; Huang M
Ann Palliat Med; 2021 Jun; 10(6):7088-7094. PubMed ID: 33832284
[TBL] [Abstract][Full Text] [Related]
14. Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond.
Inamura K
J Thorac Oncol; 2023 Sep; 18(9):e87-e88. PubMed ID: 37599050
[No Abstract] [Full Text] [Related]
15. STK11 mutation impacts CD1E expression to regulate the differentiation of macrophages in lung adenocarcinoma.
Zhang Q; Feng J; Liu K; Yang X; Huang Y; Tang B
Immun Inflamm Dis; 2023 Jul; 11(7):e958. PubMed ID: 37506141
[TBL] [Abstract][Full Text] [Related]
16. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
17. Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers.
Donnelly LL; Hogan TC; Lenahan SM; Nandagopal G; Eaton JG; Lebeau MA; McCann CL; Sarausky HM; Hampel KJ; Armstrong JD; Cameron MP; Sidiropoulos N; Deming P; Seward DJ
Carcinogenesis; 2021 Dec; 42(12):1428-1438. PubMed ID: 34849607
[TBL] [Abstract][Full Text] [Related]
18. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
[TBL] [Abstract][Full Text] [Related]
19. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
20. STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
Li A; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Nov; 18(11):e135-e138. PubMed ID: 37879773
[No Abstract] [Full Text] [Related]
[Next] [New Search]